Discovery sheds new light on the process of stem cell generation, and will help promote safer stem-cell based studies and future clinical trials.
Dr. Andras Nagy’s laboratory at the Samuel Lunenfeld Research Institute of Mount Sinai Hospital and Dr. Timo Otonkoski’s laboratory at Biomedicum Center (University of Helsinki), as well as collaborators in Europe and Canada have identified genetic abnormalities associated with reprogramming adult cells to induced pluripotent stem (iPS) cells. The findings give researchers new insights into the reprogramming process, and will help make future applications of stem cell creation and subsequent use safer. The study was published online today in Nature.
The team showed that the reprogramming process for generating iPS cells (i.e., cells that can then be ‘coaxed’ to become a variety of cell types for use in regenerative medicine) is associated with inherent DNA damage. This damage is detected in the form of genetic rearrangements and ‘copy number variations,’ which are alterations of DNA in which a region of the genome is either deleted or amplified on certain chromosomes. The variability may either be inherited, or caused by de novo mutation.
“Our analysis shows that these genetic changes are a result of the reprogramming process itself, which raises the concern that the resultant cell lines are mutant or defective,” said Dr. Nagy, a Senior Investigator at the Lunenfeld. “These mutations could alter the properties of the stem cells, affecting their applications in studying degenerative conditions and screening for drugs to treat diseases. In the longer term, this discovery has important implications in the use of these cells for replacement therapies in regenerative medicine.”
“Our study also highlights the need for rigorous characterization of generated iPS lines, especially since several groups are currently trying to enhance reprogramming efficiency,” said Dr. Samer Hussein, a McEwen post-doctoral scientist who initiated these studies with Dr. Otonkoski, before completing them with Dr. Nagy. “For example, increasing the efficiency of reprogramming may actually reduce the quality of the cells in the long run, if genomic integrity is not accurately assessed.”
The researchers used a molecular technique called single nucleotide polymorphism (SNP) analysis to study stem cell lines, and specifically to compare the number of copy number variations in both early and intermediate-stage human iPS cells with their respective parental, originating cells.
Drs. Nagy and Otonkoski and their teams found that iPS cells had more genetic abnormalities than their originating cells and embryonic stem cells. Interestingly, however, the simple process of growing the freshly generated iPS cells for a few weeks selected against the highly mutant cell lines, and thus most of the genetic abnormalities were eventually ‘weeded out.’
“However, some of the mutations are beneficial for the cells and they may survive during continued growth,” said Dr. Otonkoski, Director and Senior Scientist at the Biomedicum Stem Cell Center.
Stem cells have been widely touted as a source of great hope for use in regenerative medicine, as well as in the development of new drugs to prevent and treat illnesses including Parkinson’s disease, spinal cord injury and macular degeneration. But techniques for generating these uniquely malleable cells have also opened a Pandora’s Box of concerns and ethical quandaries. Health Canada, the U.S. Food and Drug Administration and the European Union consider stem cells to be drugs under federal legislation, and as such, subject to the same regulations.
“This work illustrates why it is so important that new medical interventions are supported by solid fundamental research,” said Dr. Paul Lasko, Scientific Director of the Canadian Institutes of Health Research Institute of Genetics. “There is a great deal of justified excitement over the therapeutic uses of reprogrammed stem cells, but this work puts up a caution flag about this, as introducing genetically compromised cells into patients may lead to other problems and be ultimately deleterious. Fortunately, this work also points to a way forward, as future research based on what we have now learned can be focused on distinguishing the particular mutations that enable cell reprogramming from those that are neutral or harmful.”
“Our results suggest that whole genome analysis should be included as part of quality control of iPS cell lines to ensure that these cells are genetically normal after the reprogramming process, and then use them for disease studies and/or clinical applications,” said Dr. Nagy.
“Rapid development of the technologies in genome-wide analyses will make this more feasible in the future,” said Dr. Otonkoski. “In addition, there is a need to further explore if other methods might mitigate the amount of DNA damage generated during the generation of stem cells,” both investigators agreed.
Dr. Nagy is a Senior Investigator at the Lunenfeld, a Professor in the Department of Molecular Genetics at the University of Toronto, and the Canada Research Chair in Stem Cells and Regeneration. The present study received support from the Stem Cell Network of Canada, the Canadian Institutes of Health Research and Ontario Ministry of Research and Innovation (for Dr. Nagy), the McEwen Centre for Regenerative Medicine Fellowship program (for Dr. Hussein), and the ESTOOLS network funding from the 6th Framework Program of the European Union (for Dr. Otonkoski). It is through an investment in scientific research that investigators can truly excel, and the Federal and Provincial support has enabled the present study and others in this area.